Catalyst Wire Dossier Catalyst Wire Dossier

Cabotegravir Ultra Long-acting

cabotegravir ultra-long-acting formulation · ViiV Healthcare
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Cabotegravir Ultra Long-acting, covering 2025-06-19 to 2025-06-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Cabotegravir Ultra Long-acting (CAB ULA) Following Switch From Cabotegravir Long-acting (CAB LA) in Healthy Adults [Phase 1]

See pricing